NICE Sample Clauses
NICE. (v) Healthwatch England and Local Healthwatch; (vi) the General Medical Council; (vii) the General Dental Council; (viii) the General Optical Council; (ix) the General Pharmaceutical Council; (x) the Healthcare Safety Investigation Branch; and (xi) the Information Commissioner; Relevant Information means the Personal Data and Non-Personal Data processed under the Delegation and this Agreement, and includes, where appropriate, “confidential patient information” (as defined under section 251 of the NHS Act), and “patient confidential information” as defined in the 2013 Report, The Information Governance Review – “To Share or Not to Share?”);
NICE. (v) Healthwatch England and Local Healthwatch; (vi) the General Medical Council; (vii) the General Dental Council; (viii) the General Optical Council; (ix) the General Pharmaceutical Council; (x) the Healthcare Safety Investigation Branch; and (xi) the Information Commissioner;
NICE. Locally defined objectives include: • Delivery of efficiencies to address the Health and Social Care financial challenge.
NICE. Attention deficit hyperactivity disorder: diagnosis and management. NICE guideline [NG87]Published date: 14 March 2018 Last updated: 13 September 2019. Available at: ▇▇▇▇▇://▇▇▇.▇▇▇▇.▇▇▇.▇▇/guidance/ng87 [Accessed June 2020] NICE. Attention deficit hyperactivity disorder in children and young people: guanfacine prolonged-release. Evidence summary [ESNM70] 22 March 2016. Available at: ▇▇▇▇▇://▇▇▇.▇▇▇▇.▇▇▇.▇▇/advice/esnm70/chapter/Key-points-from-the-evidence [Accessed May 2020]
NICE. Maintenance and monitoring for people taking medication for ADHD. Last Updated September 2019. Available at: ▇▇▇▇▇://▇▇▇▇▇▇▇▇.▇▇▇▇.▇▇▇.▇▇/pathways/attention-deficit-hyperactivity-disorder#path=view%3A/pathways/attention-deficit-hyperactivity-disorder/maintenance-and-monitoring-for-people-taking-medication-for-adhd.xml&content=view-info-category%3Aview-resources-menu [Accessed June 2020] Joint Formulary Committee. British National Formulary for Children (BNFc). May 2020 Available at: ▇▇▇▇▇://▇▇▇▇.▇▇▇▇.▇▇▇.▇▇/ [Accessed May 2020] Electronic Medicines Compendium. Summaries of Product Characteristics. Available at: ▇▇▇▇▇://▇▇▇.▇▇▇▇▇▇▇▇▇.▇▇▇.▇▇/emc [Accessed June 2020] General Medical Council. Prescribing Unlicensed Medicines. Available at: ▇▇▇▇▇://▇▇▇.▇▇▇-▇▇.▇▇▇/ethical-guidance/ethical-guidance-for-doctors/prescribing-and-managing-medicines-and-devices/prescribing-unlicensed-medicines [Accessed 17.6.20] NHS England. Responsibility for prescribing between Primary & Secondary/Tertiary Care. Publications Gateway Reference 07573. January 2018. Available at: ▇▇▇▇▇://▇▇▇.▇▇▇▇▇▇▇.▇▇▇.▇▇/wp-content/uploads/2018/03/responsibility-prescribing-between-primary-secondary-care-v2.pdf [Accessed June 2020]
NICE. COVID-19 rapid guideline: managing the long-term effects of COVID- 19. NG188. 2020. Accessed 29.04.21: ▇▇▇▇▇://▇▇▇.▇▇▇▇.▇▇▇.▇▇/guidance/NG188 6. ONS (2020) The prevalence of long COVID symptoms and COVID-19 complications. Accessed 29.04.21: ▇▇▇▇▇://▇▇▇.▇▇▇.▇▇▇.▇▇/news/statementsandletters/theprevalenceoflongcovid symptomsandcovid19complications 7. ▇▇▇▇▇ CH, ▇▇▇▇▇▇ B, ▇▇▇▇▇▇▇▇▇ T, ▇▇▇▇▇▇ MS, ▇▇▇▇▇▇▇ ▇▇, ▇▇▇▇▇▇ ▇▇, et al. Attributes and predictors of Long-COVID: analysis of COVID cases and their symptoms collected by the Covid Symptoms Study App. medRxiv [Internet]. 2020.10.19.20214494. Accessed 29.04.21: ▇▇▇▇://▇▇▇▇▇▇▇.▇▇▇/content/early/2020/10/21/2020.10.19.20214494.abstract 8. Tenforde M, ▇▇▇ ▇, ▇▇▇▇▇▇▇▇ C, al. e (2020) Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID- 19 in a Multistate Health Care Systems Network — United States, MMWR Morb Mortal Wkly Rep. 2020;ePub: Accessed 29.04.21 ▇▇▇▇://▇▇.▇▇▇.▇▇▇/10.15585/mmwr.mm6930e1external
NICE. 4.1.1 The Provider will have systems in place, as relevant and applicable, that ensure the Service is delivered in accordance with current and emerging practice
NICE. Improving Outcomes Guidance (IOG): Head and Neck Cancer – NICE (2004) • Guidance on Cancer Services – Improving Outcomes in Head and Neck Cancers – The Research Evidence NICE (2004) • Improving Supportive and Palliative Care for adults with cancer – NICE (2011) • National Cancer Peer Review • National Cancer Peer Review handbook – NCPR, Nation Cancer Action Team (2011) • Manual for Cancer Services: Head and Neck Measures Version 2.0 – NCPR Nation Cancer Action Team (2011) • Manual for Cancer services Acute Oncology Measures NCPR, National Cancer Action Team (April 2011) • Manual for Cancer Services Chemotherapy Measures – NCPR, National Cancer Action Team (June 2011) Other • Chemtherapy Services in England. National Chemotherapy Advisory Group (2009) • ▇▇▇▇▇▇▇▇ ▇▇▇▇▇: ▇▇▇.▇▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇.▇▇/▇▇▇▇ • Macmillan Cancer Care: ▇▇▇.▇▇▇▇▇▇▇▇▇.▇▇▇.▇▇/▇▇▇▇ General Overview Head and neck cancer refers to a group of biologically diverse cancers that start in the Upper Aerodigestive Tract (UAT), including: • Oral Cancer (mouth, lip and oral cavity) • Cancer of the larynx (voice box) • Cancer of the pharynx (throat) • Thyroid cancer (please see below) • Other head & neck cancers The majority of non thyroid head and neck cancers are squamous cell carcinomas. Head and neck cancers often spread to the lymph nodes of the neck, and this is often the first sign of the disease at the time of diagnosis.
NICE. Psychosis and schizophrenia in adults: prevention and management. Available at: ▇▇▇▇▇://▇▇▇.▇▇▇▇.▇▇▇.▇▇/Guidance/CG178. Accessed March 19, 2018.
NICE and ▇▇▇▇ acknowledge that: o it is in the interests of patients generally, and the consultees in each technology appraisal specifically, that all relevant information about technologies being appraised be put in the public domain; o NICE is under obligations of transparency and fairness to, amongst others, patients and other consultees in conducting each technology appraisal; and o the rights of the owners of the data provided to NICE must also be respected.